Title :

Early versus delayed invasive strategy for intermediate‐ and high‐risk acute coronary syndromes managed without P2Y 12 receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial

Author(s) :

Lemesle, Gilles [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Laine, Marc [Auteur]
Pankert, Mathieu [Auteur]
Puymirat, Etienne [Auteur]
Cuisset, Thomas [Auteur]
Boueri, Ziad [Auteur]
Maillard, Luc [Auteur]
Armero, Sébastien [Auteur]
Cayla, Guillaume [Auteur]
Bali, Laurent [Auteur]
Motreff, Pascal [Auteur]
Peyre, Jean‐pascal [Auteur]
Paganelli, Franck [Auteur]
Kerbaul, François [Auteur]
Roch, Antoine [Auteur]
Michelet, Pierre [Auteur]
Baumstarck, Karine [Auteur]
Bonello, Laurent [Auteur]

Journal title :

Clinical Cardiology

Pages :

5-12

Publisher :

Wiley

Publication date :

2018-01-22

ISSN :

0160-9289

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

According to recent literature, pretreatment with a P2Y 12 ADP receptor antagonist before coronary angiography appears no longer suitable in non–ST‐segment elevation acute coronary syndrome (NSTE‐ACS) due to an unfavorable ...
Show more >According to recent literature, pretreatment with a P2Y 12 ADP receptor antagonist before coronary angiography appears no longer suitable in non–ST‐segment elevation acute coronary syndrome (NSTE‐ACS) due to an unfavorable risk–benefit ratio. Optimal delay of the invasive strategy in this specific context is unknown. We hypothesize that without P2Y 12 ADP receptor antagonist pretreatment, a very early invasive strategy may be beneficial. The EARLY trial (Early or Delayed Revascularization for Intermediate‐ and High‐Risk Non–ST‐Segment Elevation Acute Coronary Syndromes?) is a prospective, multicenter, randomized, controlled, open‐label, 2‐parallel‐group study that plans to enroll 740 patients. Patients are eligible if the diagnosis of intermediate‐ or high‐risk NSTE‐ACS is made and an invasive strategy intended. Patients are randomized in a 1:1 ratio. In the control group, a delayed strategy is adopted, with the coronary angiography taking place between 12 and 72 hours after randomization. In the experimental group, a very early invasive strategy is performed within 2 hours. A loading dose of a P2Y 12 ADP receptor antagonist is given at the time of intervention in both groups. Recruitment began in September 2016 (n = 558 patients as of October 2017). The primary endpoint is the composite of cardiovascular death and recurrent ischemic events at 1 month. The EARLY trial aims to demonstrate the superiority of a very early invasive strategy compared with a delayed strategy in intermediate‐ and high‐risk NSTE‐ACS patients managed without P2Y 12 ADP receptor antagonist pretreatment.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011

Source :

Harvested from HAL